logo

Cubist Pharmaceuticals’ Stock Rises On Takeover Rumors
By: Daniel Shepard   Saturday, April 04, 2009 11:18 AM

Vote for next session
The next market session will close:

Cubist Pharmaceuticals’ (CBST) stock was one of the better performers on a percentage basis in trading Friday, as the shares soared $3.52 for a 22.10% gain to close at $19.45. The volume was an incredible 6,099,795 compared to a three month daily average of 1,297,830.

The stock is rising on buyout rumors, more specifically, that Swiss pharmaceutical giant Novartis (NVS) is interested in acquiring the company and could make a bid for the company as soon as Monday.

Trading in the stock’s options also lent credence to the fact that traders believe the company could be an acquisition candidate. The April 2009 17.50 calls traded 10,918 contracts against an open interest of just 1,145, the April 2009 20 calls traded 15,567 contracts, against an open interest of just 140.

With the April contracts expiring just two weeks from today, the options actions also indicate that traders feel, a deal if it happens, will happen sooner rather than later. While there was also heavy action in the May 2009 calls, the 17.50 and 20 calls for that month “only” traded 5,343 and 5,071 contracts respectively.

The puts on the other hand, saw light action. The April 2009 17.50 puts had a volume of 2,395, while the May puts with the same strike had volume of just 289 contracts.


(0)
No Comments
Post Comment
Name:  
Alert for new comments:
Your email:
Your Website:
Title:
Comments:
   
 
 
 
 
   
 

The above story is the opinion of the author only and it does not reflect iStockAnalyst opinion. Further, the author is not personally advising you regarding the suitability of the story for your investment needs. In no event iStockAnalyst will be liable for any loss or damage including without limitation, indirect or consequential loss or damage, or any loss or damage whatsoever arising from or arising out of, or in connection with the use of this information. Please consult your investment advisor before making any investment decision.
  
Advertisement
Popular Articles
Related Press Releases
Advertisement
Partner Center
Recent Articles by Daniel Shepard



Subscribe to Email Alerts rss feed or RSS feeds rss feed for articles from more than 500 contributors, press releases, SEC filings and full text news from more than four thousand sources.
Fundamental data is provided by Zacks Investment Research, market data is provided by AlphaTrade. , and Commentary and Press Releases provided by Quotemedia